Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

The development of newer classes of antidepressants and second-generation antiepileptic drugs has created unprecedented opportunities for the treatment of chronic pain. These drugs modulate pain transmission by interacting with specific neurotransmitters and ion channels. The actions of antidepressants and antiepileptic drugs differ in neuropathic and non-neuropathic pain, and agents within each medication class have varying degrees of efficacy. Tricyclic antidepressants (e.g., amitriptyline, nortriptyline, desipramine) and certain novel antidepressants (i.e., bupropion, venlafaxine, duloxetine) are effective in the treatment of neuropathic pain. The analgesic effect of these drugs is independent of their antidepressant effect and appears strongest in agents with mixed-receptor or predominantly noradrenergic activity, rather than serotoninergic activity. First-generation antiepileptic drugs (i.e., carbamazepine, phenytoin) and second-generation antiepileptic drugs (e.g., gabapentin, pregabalin) are effective in the treatment of neuropathic pain. The efficacy of antidepressants and antiepileptic drugs in the treatment of neuropathic pain is comparable; tolerability also is comparable, but safety and side effect profiles differ. Tricyclic antidepressants are the most cost-effective agents, but second-generation antiepileptic drugs are associated with fewer safety concerns in elderly patients. Tricyclic antidepressants have documented (although limited) efficacy in the treatment of fibromyalgia and chronic low back pain. Recent evidence suggests that duloxetine and pregabalin have modest efficacy in patients with fibromyalgia.

Chronic pain affects approximately 86 million Americans, substantially reducing their quality of life.1 The socioeconomic burden also is significant, with chronic pain estimated to cost $90 billion annually in medical expenses and reduced work productivity.1

Our understanding of many chronic pain disorders is evolving rapidly, and the development of newer antidepressant drug classes and second-generation antiepileptic drugs has created unprecedented opportunities for the treatment of chronic pain.

Strength of Recommendations

Key clinical recommendation Label References

Tricyclic antidepressants may be used for treatment of chronic neuropathic and non-neuropathic pain syndromes.

A

5,8,11,21

Tricyclic antidepressants are more effective than SSRIs in the treatment of neuropathic pain syndromes. An estimated 2.6 patients must be treated with tricyclic antidepressants and 6.7 patients with SSRIs to have one patient with more than 50 percent pain relief.

B

6,14

Serotoninergic antidepressants and currently approved antiepileptic drugs have little documented efficacy and therefore should not be used as first-line medications in the treatment of non-neuropathic pain.

B

7,8,3033


SSRIs = selective serotonin reuptake inhibitors.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series.

Strength of Recommendations

View Table

Strength of Recommendations

Key clinical recommendation Label References

Tricyclic antidepressants may be used for treatment of chronic neuropathic and non-neuropathic pain syndromes.

A

5,8,11,21

Tricyclic antidepressants are more effective than SSRIs in the treatment of neuropathic pain syndromes. An estimated 2.6 patients must be treated with tricyclic antidepressants and 6.7 patients with SSRIs to have one patient with more than 50 percent pain relief.

B

6,14

Serotoninergic antidepressants and currently approved antiepileptic drugs have little documented efficacy and therefore should not be used as first-line medications in the treatment of non-neuropathic pain.

B

7,8,3033


SSRIs = selective serotonin reuptake inhibitors.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series.

Chronic and Acute Pain

Chronic and acute pain differ significantly in several important respects and require different treatment approaches. Acute pain is a protective response to injury, whereas chronic pain may be a maladaptive response. Acute pain most often is nociceptive (i.e., resulting from injury or inflammation of somatic or visceral tissue). Chronic pain may be nociceptive or neuropathic (i.e., resulting from neuronal maintenance of pain either peripherally or in the central nervous system [CNS]).

Nociceptive pain usually is treated with anti-inflammatory or analgesic medications. Neuropathic pain typically is treated with medications that influence neurotransmitters (e.g., antidepressants, antiepileptic drugs), and treatment with opioids is reserved for patients with refractory neuropathic pain.

Peripheral neuropathic pain typically is described as burning, sharp, shooting, or aching, and it may be associated with tingling, dysesthesias, or numbness. Allodynia (i.e., a painful sensation from a normally nonpainful stimulus) is common. Pain often is worse at night and may be exacerbated by activity.

Common non-cancer pain syndromes may be neuropathic (peripheral or central) or non-neuropathic (Table 1).2 It is likely that both peripheral and central mechanisms contribute to the persistence of most types of neuropathic pain. Neuropathic pain also may coexist with non-neuropathic pain (e.g., in some patients with chronic low back pain).

TABLE 1

Common Non-Cancer Pain Syndromes

Peripheral neuropathic pain Central neuropathic pain Non-neuropathic pain*

Complex regional pain syndrome

Multiple sclerosis

Arthritis

Human immunodeficiency virus sensory neuropathy

Myelopathies

 Inflammatory arthritis

Idiopathic peripheral neuropathy

Parkinson's disease

Osteoarthritis

Infection

Poststroke pain

Chronic low back pain

Metabolic disorders

Chronic neck pain

Alcohol and other toxins

Fibromyalgia

Diabetic neuropathy

Post-traumatic pain

Nutritional deficiencies

Nerve compression or entrapment

Phantom limb pain

Postherpetic neuralgia

Trigeminal neuralgia


*—Elements of neuropathic pain may be superimposed on the underlying disorder

Information from reference 2.

TABLE 1   Common Non-Cancer Pain Syndromes

View Table

TABLE 1

Common Non-Cancer Pain Syndromes

Peripheral neuropathic pain Central neuropathic pain Non-neuropathic pain*

Complex regional pain syndrome

Multiple sclerosis

Arthritis

Human immunodeficiency virus sensory neuropathy

Myelopathies

 Inflammatory arthritis

Idiopathic peripheral neuropathy

Parkinson's disease

Osteoarthritis

Infection

Poststroke pain

Chronic low back pain

Metabolic disorders

Chronic neck pain

Alcohol and other toxins

Fibromyalgia

Diabetic neuropathy

Post-traumatic pain

Nutritional deficiencies

Nerve compression or entrapment

Phantom limb pain

Postherpetic neuralgia

Trigeminal neuralgia


*—Elements of neuropathic pain may be superimposed on the underlying disorder

Information from reference 2.

Mechanism of Action of Antidepressants and Antiepileptic Drugs in Pain Syndromes

Transmission of painful stimuli through the spinal column and CNS is modulated by excitatory and inhibitory neurotransmitters, as well as actions at sodium and calcium channels. Norepinephrine and serotonin may be excitatory or inhibitory, but they are functionally inhibitory on pain transmission; glutamate is the other important excitatory neurotransmitter. The most important inhibitory neurotransmitter is γ-aminobutyric acid (GABA). Antidepressants and antiepileptic drugs are thought to relieve neuropathic pain through interaction with specific neurotransmitters and ion channels (Table 2).3

TABLE 2

Suggested Mechanisms of Action for Antidepressants and Antiepileptic Drugs Used to Treat Chronic Pain

Mechanism of action Drugs

Inhibition of norepinephrine reuptake

Tricyclic antidepressants (secondary amines): desipramine (Norpramin), nortriptyline (Pamelor)

Inhibition of norepinephrine and serotonin reuptake

Tricyclic antidepressants (tertiary amines): amitriptyline (Elavil), imipramine (Tofranil)

Novel antidepressants: venlafaxine (Effexor), duloxetine (Cymbalta)

Cyclobenzaprine (Flexeril)

Blockade of sodium channel

Antiepileptic drugs: carbamazepine (Tegretol), gabapentin (Neurontin), lamotrigine (Lamictal)

Blockade of calcium channel

Antiepileptic drugs: gabapentin, pregabalin (Lyrica)*

Enhancement of γ-aminobutyric acid

Antiepileptic drug: carbamazepine

Spasmolytic drug: baclofen (Lioresal)


*—Investigational drug (approval pending from U.S. Food and Drug Administration).

Adapted with permissions from Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2002;55(5 suppl 1):S42.

TABLE 2   Suggested Mechanisms of Action for Antidepressants and Antiepileptic Drugs Used to Treat Chronic Pain

View Table

TABLE 2

Suggested Mechanisms of Action for Antidepressants and Antiepileptic Drugs Used to Treat Chronic Pain

Mechanism of action Drugs

Inhibition of norepinephrine reuptake

Tricyclic antidepressants (secondary amines): desipramine (Norpramin), nortriptyline (Pamelor)

Inhibition of norepinephrine and serotonin reuptake

Tricyclic antidepressants (tertiary amines): amitriptyline (Elavil), imipramine (Tofranil)

Novel antidepressants: venlafaxine (Effexor), duloxetine (Cymbalta)

Cyclobenzaprine (Flexeril)

Blockade of sodium channel

Antiepileptic drugs: carbamazepine (Tegretol), gabapentin (Neurontin), lamotrigine (Lamictal)

Blockade of calcium channel

Antiepileptic drugs: gabapentin, pregabalin (Lyrica)*

Enhancement of γ-aminobutyric acid

Antiepileptic drug: carbamazepine

Spasmolytic drug: baclofen (Lioresal)


*—Investigational drug (approval pending from U.S. Food and Drug Administration).

Adapted with permissions from Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2002;55(5 suppl 1):S42.

TRICYCLIC ANTIDEPRESSANTS

Tricyclic antidepressants are thought to affect pain transmission in the spinal cord by inhibiting the reuptake of norepinephrine and serotonin, both of which influence descending pain pathways. In addition, histamine H1-receptor affinity (associated with sedation) may be correlated with the analgesic effect of antidepressants. Amitriptyline (Elavil) also has an analgesic effect in patients with acute pain.4

Tricyclic antidepressants may be categorized as secondary or tertiary amines. Secondary amines such as nortriptyline (Pamelor) and desipramine (Norpramin) show relatively selective inhibition of norepinephrine reuptake. Tertiary amines such as amitriptyline and imipramine (Tofranil) show more balanced inhibition of norepinephrine and serotonin, but they also have greater anticholinergic side effects.

The novel antidepressants venlafaxine (Effexor) and duloxetine (Cymbalta) have balanced inhibition of serotonin and norepinephrine reuptake without blockade of other neuroreceptors that are responsible for typical tricyclic side effects. The mechanism of action of bupropion (Wellbutrin) is uncertain but involves blockade of dopamine uptake.

ANTIEPILEPTIC DRUGS

Antiepileptic drugs act at several sites that may be relevant to pain, but the precise mechanism of their analgesic effect remains unclear. These agents are thought to limit neuronal excitation and enhance inhibition. Relevant sites of action include voltage-gated ion channels (i.e., sodium and calcium channels), ligand-gated ion channels, the excitatory receptors for glutamate and N-methyl-D-aspartate, and the inhibitory receptors for GABA and glycine (Table 2).3

Antiepileptic drugs may be categorized as first or second generation. The second-generation agents are better tolerated, cause less sedation, and have fewer CNS side effects.

Clinical Efficacy

The efficacy of antidepressants and antiepileptic drugs varies dramatically in neuropathic and non-neuropathic pain syndromes. Specific agents within each medication class can vary in effectiveness. Table 3 lists typical dosages and side effects of medications commonly used to treat chronic pain. Table 4419 reviews the levels of evidence for these agents.

TABLE 3

Antidepressants and Antiepileptic Drugs Used in Chronic Pain Syndromes

Drug Dosage Side effects, contraindications, and comments

Antidepressants

Tricyclic antidepressants

Side effects: dry mouth, constipation, urinary retention, sedation, weight gain

Contraindications: cardiac conduction abnormalities, recent cardiac events, narrow-angle glaucoma

Amitriptyline (Elavil),* imipramine (Tofranil)*

10 to 25 mg at bedtime; increase by 10 to 25 mg per week up to 75 to 150 mg at bedtime or a therapeutic drug level.

Tertiary amines have greater anticholinergic side effects; therefore, these agents should not be used in elderly patients.

Desipramine (Norpramin),* nortriptyline (Pamelor)*

25 mg in the morning or at bedtime; increase by 25 mg per week up to 150 mg per day or a therapeutic drug level.

Secondary amines have fewer anticholinergic side effects.

Selective serotonin reuptake inhibitors

Fluoxetine (Prozac),* paroxetine (Paxil)*

10 to 20 mg per day; up to 80 mg per day for fibromyalgia.

Side effects: nausea, sedation, decreased libido, sexual dysfunction, headache, weight gain

Efficacy in pain syndromes is relatively poor.

Novel antidepressants

Bupropion (Wellbutrin)*

100 mg per day; increase by 100 mg per week up to 200 mg twice daily (400 mg per day).

Side effects: anxiety, insomnia or sedation, weight loss, seizures (at dosages above 450 mg per day)

Venlafaxine (Effexor)*

37.5 mg per day; increase by 37.5 mg per week up to 300 mg per day.

Side effects: headache, nausea, sweating, sedation, hypertension, seizures

Serotoninergic properties in dosages below 150 mg per day; mixed serotoninergic and noradrenergic properties in dosages above 150 mg per day

Duloxetine (Cymbalta)*

20 to 60 mg per day taken once or twice daily in divided doses (for depression); 60 mg twice daily for fibromyalgia

Side effects: nausea, dry mouth, constipation, dizziness, insomnia

Antiepileptic drugs

First-generation agents

Carbamazepine (Tegretol)

200 mg per day; increase by 200 mg per week up to 400 mg three times daily (1,200 mg per day).

Side effects: dizziness, diplopia, nausea

Treatment can result in aplastic anemia.

Phenytoin (Dilantin)*

100 mg at bedtime; increase weekly up to 500 mg at bedtime.

Side effects: dizziness, ataxia, slurred speech, confusion, nausea, rash

Treatment can result in blood dyscrasias and hepatotoxicity.

Second-generation agents

Gabapentin (Neurontin)

100 to 300 mg at bedtime; increase by 100 mg every 3 days up to 1,800 to 3,600 mg per day taken in divided doses three times daily.

Side effects: drowsiness, dizziness, fatigue, nausea, sedation, weight gain

Pregabalin (Lyrica)

150 mg at bedtime for diabetic neuropathy; 300 mg twice daily for postherpetic neuralgia.

Side effects: drowsiness, dizziness, fatigue, nausea, sedation, weight gain

Lamotrigine (Lamictal)*

50 mg per day; increase by 50 mg every 2 weeks up to 400 mg per day.

Side effects: dizziness, constipation, nausea; rarely, life-threatening rashes


*—Not approved by the U.S. Food and Drug Administration for treatment of neuropathic pain.

TABLE 3   Antidepressants and Antiepileptic Drugs Used in Chronic Pain Syndromes

View Table

TABLE 3

Antidepressants and Antiepileptic Drugs Used in Chronic Pain Syndromes

Drug Dosage Side effects, contraindications, and comments

Antidepressants

Tricyclic antidepressants

Side effects: dry mouth, constipation, urinary retention, sedation, weight gain

Contraindications: cardiac conduction abnormalities, recent cardiac events, narrow-angle glaucoma

Amitriptyline (Elavil),* imipramine (Tofranil)*

10 to 25 mg at bedtime; increase by 10 to 25 mg per week up to 75 to 150 mg at bedtime or a therapeutic drug level.

Tertiary amines have greater anticholinergic side effects; therefore, these agents should not be used in elderly patients.

Desipramine (Norpramin),* nortriptyline (Pamelor)*

25 mg in the morning or at bedtime; increase by 25 mg per week up to 150 mg per day or a therapeutic drug level.

Secondary amines have fewer anticholinergic side effects.

Selective serotonin reuptake inhibitors

Fluoxetine (Prozac),* paroxetine (Paxil)*

10 to 20 mg per day; up to 80 mg per day for fibromyalgia.

Side effects: nausea, sedation, decreased libido, sexual dysfunction, headache, weight gain

Efficacy in pain syndromes is relatively poor.

Novel antidepressants

Bupropion (Wellbutrin)*

100 mg per day; increase by 100 mg per week up to 200 mg twice daily (400 mg per day).

Side effects: anxiety, insomnia or sedation, weight loss, seizures (at dosages above 450 mg per day)

Venlafaxine (Effexor)*

37.5 mg per day; increase by 37.5 mg per week up to 300 mg per day.

Side effects: headache, nausea, sweating, sedation, hypertension, seizures

Serotoninergic properties in dosages below 150 mg per day; mixed serotoninergic and noradrenergic properties in dosages above 150 mg per day

Duloxetine (Cymbalta)*

20 to 60 mg per day taken once or twice daily in divided doses (for depression); 60 mg twice daily for fibromyalgia

Side effects: nausea, dry mouth, constipation, dizziness, insomnia

Antiepileptic drugs

First-generation agents

Carbamazepine (Tegretol)

200 mg per day; increase by 200 mg per week up to 400 mg three times daily (1,200 mg per day).

Side effects: dizziness, diplopia, nausea

Treatment can result in aplastic anemia.

Phenytoin (Dilantin)*

100 mg at bedtime; increase weekly up to 500 mg at bedtime.

Side effects: dizziness, ataxia, slurred speech, confusion, nausea, rash

Treatment can result in blood dyscrasias and hepatotoxicity.

Second-generation agents

Gabapentin (Neurontin)

100 to 300 mg at bedtime; increase by 100 mg every 3 days up to 1,800 to 3,600 mg per day taken in divided doses three times daily.

Side effects: drowsiness, dizziness, fatigue, nausea, sedation, weight gain

Pregabalin (Lyrica)

150 mg at bedtime for diabetic neuropathy; 300 mg twice daily for postherpetic neuralgia.

Side effects: drowsiness, dizziness, fatigue, nausea, sedation, weight gain

Lamotrigine (Lamictal)*

50 mg per day; increase by 50 mg every 2 weeks up to 400 mg per day.

Side effects: dizziness, constipation, nausea; rarely, life-threatening rashes


*—Not approved by the U.S. Food and Drug Administration for treatment of neuropathic pain.

TABLE 4

Study-Quality Ratings for Antidepressants and Antiepileptic Drugs in Chronic Pain Syndromes

Neuropathic pain Non-neuropathic pain
DrugTrigeminal neuralgiaDiabetic neuropathy or postherpetic neuralgia Fibromyalgia Low back or other pain

Antidepressants

Amitriptyline (Elavil)48

1

1

2

Fluoxetine (Prozac)9

3

Bupropion (Wellbutrin)10

2

Venlafaxine (Effexor)11

2

Duloxetine (Cymbalta)12,13

1

1

Antiepileptics

First generation

Carbamazepine (Tegretol)14

1

3

Phenytoin (Dilantin)14

3

Second generation

Gabapentin (Neurontin)15,16

1

Lamotrigine (Lamictal)17*

3

Pregabalin (Lyrica)18,19

2

2


1 = good-quality patient-oriented evidence; 2 = limited-quality patient-oriented evidence; 3 = other evidence.

*—Efficacy of lamotrigine as an adjunct to carbamazepine or phenytoin.

†—Investigational drug (approval pending from U.S. Food and Drug Administration).

Information from references 4 through 19.

TABLE 4   Study-Quality Ratings for Antidepressants and Antiepileptic Drugs in Chronic Pain Syndromes

View Table

TABLE 4

Study-Quality Ratings for Antidepressants and Antiepileptic Drugs in Chronic Pain Syndromes

Neuropathic pain Non-neuropathic pain
DrugTrigeminal neuralgiaDiabetic neuropathy or postherpetic neuralgia Fibromyalgia Low back or other pain

Antidepressants

Amitriptyline (Elavil)48

1

1

2

Fluoxetine (Prozac)9

3

Bupropion (Wellbutrin)10

2

Venlafaxine (Effexor)11

2

Duloxetine (Cymbalta)12,13

1

1

Antiepileptics

First generation

Carbamazepine (Tegretol)14

1

3

Phenytoin (Dilantin)14

3

Second generation

Gabapentin (Neurontin)15,16

1

Lamotrigine (Lamictal)17*

3

Pregabalin (Lyrica)18,19

2

2


1 = good-quality patient-oriented evidence; 2 = limited-quality patient-oriented evidence; 3 = other evidence.

*—Efficacy of lamotrigine as an adjunct to carbamazepine or phenytoin.

†—Investigational drug (approval pending from U.S. Food and Drug Administration).

Information from references 4 through 19.

NEUROPATHIC PAIN

Antidepressants

Meta-analyses5,6 have confirmed the efficacy of tricyclic antidepressants in the treatment of neuropathic pain. Nontricyclic antidepressants show variable degrees of efficacy in patients with neuropathic pain.

Antidepressants with mixed-receptor or noradrenergic activity appear to have the greatest analgesic effect in patients with neuropathic pain. Predominantly serotoninergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), often are ineffective in treating chronic pain.5,20 Amitriptyline and its metabolite nortriptyline have the best documented efficacy in the treatment of neuropathic and non-neuropathic pain syndromes.4 The novel antidepressants bupropion,10 venlafaxine,11 and duloxetine12 also have proved effective in patients with neuropathic pain.

The efficacy of tricyclic antidepressants in the treatment of neuropathic pain appears to be independent of their antidepressant effect,21 and patients with pain but no depression respond to these agents. Although pain reduction occurs at dosages lower than those typically used to treat depression, a dose response between 25 and 100 mg has been noted.22 Some experts recommend documenting a therapeutic level of a tricyclic antidepressant before concluding that the drug is clinically ineffective in a patient with chronic pain.

Antiepileptic Drugs

Specific antiepileptic drugs are effective in the treatment of patients with neuropathic pain.14 Of the first-generation agents, carbamazepine (Tegretol) is indicated for the treatment of trigeminal neuralgia. Carbamazepine also has shown modest efficacy in trials involving patients with diabetic neuropathy or postherpetic neuralgia.14 Phenytoin (Dilantin) is used infrequently to treat chronic pain.

Of the second-generation antiepileptic drugs, gabapentin (Neurontin) has the best documented efficacy in the treatment of neuropathic pain. Gabapentin has been proved superior to placebo in patients with painful diabetic neuropathy15 or postherpetic neuralgia.16 In these trials,15,16 effective dosages have ranged from 2,400 to 3,600 mg per day.

One study23 of patients with painful diabetic neuropathy found no significant effect for gabapentin in a dosage of 900 mg per day. The efficacy of this drug in other pain syndromes that may have a neuropathic component (e.g., persistent postoperative pain) has been of borderline statistical significance.24 The investigational drug pregabalin (Lyrica) has documented efficacy in the treatment of diabetic neuropathy18 and postherpetic neuralgia.19 Approval of pregabalin by the U.S. Food and Drug Administration is pending.

Lamotrigine (Lamictal) has been proved modestly effective in patients with trigeminal neuralgia,17 neuropathy associated with human immunodeficiency virus infection,25 and poststroke pain.26 The drug is ineffective in patients with unspecified refractory neuropathic pain.27 The use of lamotrigine is limited by potentially life-threatening rashes.

Comparative Efficacies

Antidepressants and antiepileptic drugs have comparable efficacy in patients with neuropathic pain. However, the drug classes (and individual agents within each class) differ in safety, tolerability, and side effect profiles.28

In a meta-analysis28 of trials of antidepressants and antiepileptic drugs in patients with neuropathic pain, the estimated number needed to treat for significant reduction of pain was 2.6 with tricyclic antidepressants, 6.7 with SSRIs, 2.5 with sodium channel–blocking antiepileptic drugs (i.e., phenytoin and carbamazepine), and 4.1 with gabapentin. Another meta-analysis5 found no significant difference between antidepressants and antiepileptic drugs in the reduction of neuropathic pain.

A small randomized, double-blind, controlled trial29 of gabapentin and amitriptyline in patients with diabetic neuropathy found that both agents were effective, with no significant differences. Tolerability also was comparable.

NON-NEUROPATHIC PAIN

The efficacy of tricyclic antidepressants has been documented in a variety of non-neuropathic pain syndromes. Most other antidepressants and most antiepileptic drugs have little or no documented efficacy in the treatment of non-neuropathic pain.

Fibromyalgia

Analysis of controlled trials on the treatment of fibromyalgia is limited by differences in outcome measures, inconsistent reporting of associated depression, and conflicting results.30 A meta-analysis31 found that antidepressants were mildly beneficial in reducing pain severity and improving sleep and overall well-being, and mildly effective in reducing fatigue; treatment with these agents also showed a trend for a beneficial effect on tender points.

In one study,32 30 to 47 percent of patients with fibromyalgia who were treated with amitriptyline reported moderate or marked improvement of pain. However, similar efficacy was reported for other antidepressants, tranquilizers, cyclobenzaprine (Flexeril), nonsteroidal anti-inflammatory drugs, exercise, and physical therapy.

Tricyclic antidepressants have the best documented efficacy in patients with fibromyalgia, but the treatment effect is modest and tends to wane over time.33 Although fluoxetine (Prozac) has shown no efficacy in a conventional dosage (20 mg per day), a study9 of dosages of up to 80 mg per day showed significant efficacy. Cyclobenzaprine, a muscle relaxant that structurally is a tricyclic agent, also has shown modest efficacy in patients with fibromyalgia.34

Recently, duloxetine in a dosage of 60 mg twice daily was shown to improve pain and global measures of fibromyalgia, compared with placebo.13 The improvement occurred regardless of baseline depression status.

Of the antiepileptic drugs, only pregabalin has demonstrated efficacy in the treatment of fibromyalgia. Patients taking 450 mg per day reported reduced pain and fatigue, and improved sleep.34

Low Back Pain

A recent meta-analysis7 found that patients with chronic back pain who were treated with antidepressants had a small but significant decrease in pain. However, their ability to perform activities of daily living did not improve. Efficacy was less for antidepressants with predominantly serotoninergic activity.

Other Chronic Pain Disorders

One review8 evaluated the efficacy of antidepressants in the treatment of a variety of pain disorders. The non-neuropathic pain disorders included osteoarthritis and rheumatoid arthritis, chronic low back pain, and other chronic pain disorders (not specified). In the arthritis studies, 26 to 68 percent of patients were noted to have a 50 percent or greater improvement in pain; however, the studies had small sample sizes and methodologic flaws.8

Clinical Considerations

Because efficacy in neuropathic pain is similar for antidepressants and antiepileptic drugs, initial drug selection is based on side effects, contraindications, coexisting conditions, and cost (Table 5).2 Patients with associated anxiety, depression, or sleep disturbance may benefit from a tricyclic or novel antidepressant, although gabapentin and pregabalin also appear to reduce anxiety. Tricyclic antidepressants are significantly less expensive than second-generation antiepileptic drugs.

TABLE 5

Clinical Guidelines for the Treatment of Chronic Pain

All chronic pain

Use of a pain scale facilitates clinical evaluation of the patient's response to a therapeutic drug trial.

An assessment of quality of life and activities of daily living should be incorporated into the clinical evaluation of the therapeutic drug trial.

Identification of psychiatric comorbidity may suggest the use of an antidepressant for nonpain indications.

Neuropathic pain

A tricyclic antidepressant is the preferred initial therapy if the patient has coexisting insomnia, anxiety, or depression, or if cost is a consideration.

An antiepileptic drug (e.g., gabapentin [Neurontin]) is preferred if the patient cannot tolerate the side effects of tricyclic antidepressants, has cardiac contraindications to the use of tricyclic antidepressants (e.g., conduction abnormalities, recent cardiac event), or is a “frail elder.”

Titrate the selected medication to achieve clinical effect or to the maximum tolerated dosage (see Table 3). With gabapentin, if no effect is seen at a dosage of 1,800 mg per day, discontinue the drug; if a partial effect occurs, titrate the drug to a dosage of 2,400 to 3,600 mg per day.

Monitor response to treatment.

If monotherapy is tolerated but only partially effective, combine an antidepressant with an antiepileptic drug.

If monotherapy is poorly tolerated or ineffective, choose a first-line agent from a different medication class or use a second-line agent (e.g., bupropion [Wellbutrin], venlafaxine [Effexor]).

If pain relief remains inadequate, consider use of a short-acting or long-acting opioid or tramadol (Ultram).

Non-neuropathic pain

Exercise is the primary therapy for chronic low back pain and fibromyalgia.

Begin treatment of low back pain with a nonsteroidal anti-inflammatory drug (not effective in the treatment of fibromyalgia).

Consider use of a tricyclic antidepressant as a pain adjuvant to promote sleep and alleviate muscle spasm.

In appropriately selected patients, consider use of a short- or long-acting opioid or tramadol.

Empiric use of antiepileptic drugs such as gabapentin is not justified by the current literature but is common practice in pain clinics.


Information from reference 2.

TABLE 5   Clinical Guidelines for the Treatment of Chronic Pain

View Table

TABLE 5

Clinical Guidelines for the Treatment of Chronic Pain

All chronic pain

Use of a pain scale facilitates clinical evaluation of the patient's response to a therapeutic drug trial.

An assessment of quality of life and activities of daily living should be incorporated into the clinical evaluation of the therapeutic drug trial.

Identification of psychiatric comorbidity may suggest the use of an antidepressant for nonpain indications.

Neuropathic pain

A tricyclic antidepressant is the preferred initial therapy if the patient has coexisting insomnia, anxiety, or depression, or if cost is a consideration.

An antiepileptic drug (e.g., gabapentin [Neurontin]) is preferred if the patient cannot tolerate the side effects of tricyclic antidepressants, has cardiac contraindications to the use of tricyclic antidepressants (e.g., conduction abnormalities, recent cardiac event), or is a “frail elder.”

Titrate the selected medication to achieve clinical effect or to the maximum tolerated dosage (see Table 3). With gabapentin, if no effect is seen at a dosage of 1,800 mg per day, discontinue the drug; if a partial effect occurs, titrate the drug to a dosage of 2,400 to 3,600 mg per day.

Monitor response to treatment.

If monotherapy is tolerated but only partially effective, combine an antidepressant with an antiepileptic drug.

If monotherapy is poorly tolerated or ineffective, choose a first-line agent from a different medication class or use a second-line agent (e.g., bupropion [Wellbutrin], venlafaxine [Effexor]).

If pain relief remains inadequate, consider use of a short-acting or long-acting opioid or tramadol (Ultram).

Non-neuropathic pain

Exercise is the primary therapy for chronic low back pain and fibromyalgia.

Begin treatment of low back pain with a nonsteroidal anti-inflammatory drug (not effective in the treatment of fibromyalgia).

Consider use of a tricyclic antidepressant as a pain adjuvant to promote sleep and alleviate muscle spasm.

In appropriately selected patients, consider use of a short- or long-acting opioid or tramadol.

Empiric use of antiepileptic drugs such as gabapentin is not justified by the current literature but is common practice in pain clinics.


Information from reference 2.

Sedation and weight gain are common side effects of tricyclic antidepressants and gabapentin. Tricyclic antidepressants should not be used in patients with cardiac conduction abnormalities, recent cardiac events, or narrow-angle glaucoma. Elderly patients should not be treated with tertiary amines because of the greater anticholinergic effects of these agents.

Even when drug therapies for painful neuropathies are successful, there is only a 30 to 50 percent reduction of pain. A combination of drugs that target different sites and receptors may be reasonable, although this approach has not been evaluated.2 Opiates2,35 and tramadol (Ultram)2 have been proved effective in the treatment of neuropathic and non-neuropathic pain.

Nonpharmacologic treatments (e.g., exercise, behavioral therapies) are particularly important in patients with non-neuropathic pain syndromes. Currently available medications have limited benefit in these syndromes.

The Authors

MORRIS MAIZELS, M.D., is a member of the Department of Family Medicine at Kaiser Permanente, Woodland Hills, Calif., as well as founder and director of the Woodland Hills Headache Clinic. Dr. Maizels received his medical degree from the University of Washington School of Medicine, Seattle, and completed residency training at the Antelope Valley Family Practice Residency of the University of California, Los Angeles. Dr. Maizels is a member of the board of directors of the American Headache Society and an associate editor of Headache.

BILL MCCARBERG, M.D., is founder of the Chronic Pain Management Program for Kaiser Permanente, San Diego, and assistant clinical professor in the Department of Family Practice at the University of California, San Diego, School of Medicine. Dr. McCarberg graduated from Northwestern University Medical School, Chicago, and completed a family practice residency at Highland Hospital, Rochester, N.Y. He has served on the board of directors of the American Pain Society and currently is co-president of the Western Pain Society.

Address correspondence to Morris Maizels, Department of Family Practice, Kaiser Permanente, 5601 DeSoto Ave., Woodland Hills, CA 91365 (e-mail: morris.maizels@kp.org). Reprints are not available from the authors.

The authors indicate that they do not have any conflicts of interest. Dr. Maizels is on the speakers' bureaus for Merck & Co., Inc., and Pfizer Inc., and has been a consultant for GlaxoSmithKline, Merck & Co., Inc., and Pfizer Inc. Dr. McCarberg is on the speakers' bureaus for Endo Pharmaceuticals, Janssen Pharmaceutica Products, L.P., Ortho-McNeill Pharmaceutical, Pfizer Inc., and the Purdue Frederick Company.

REFERENCES

1. Moskowitz MA. Advances in understanding chronic pain: mechanisms of pain modulation and relationship to treatment. Neurology. 2002;59(5 suppl 2):S1.

2. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-34.

3. Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology. 2002;55(5 suppl 1):S41-6.

4. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996;8:459-76.

5. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68:217-27.

6. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20:449-58.

7. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta- analysis. Arch Intern Med. 2002;162:19-24.

8. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992;49:205-19.

9. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191-7.

10. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57:1583-8.

11. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60:1284-9.

12. Wernicke J, Lu Y, D'Souza DN, Waninger A, Tran P. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). In: Abstracts of the 2d Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society. May 2004. J Pain. 2004;5(3 suppl 1):S48.

13. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-84.

14. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047-52.

15. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-6.

16. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.

17. McCleane GJ. Lamotrigine in the management of neuropathic pain: a review of the literature. Clin J Pain. 2000;16:321-6.

18. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-38.

19. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-83.

20. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-6.

21. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37:589-96.

22. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia. 1993;48:281-5.

23. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251-2.

24. Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-66.

25. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-9.

26. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184-90.

27. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain. 1999;83:105-7.

28. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55:915-20.

29. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931-7.

30. White KP, Harth M. An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain. 1996;64:211-9.

31. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15:659-66.

32. Goldenberg DL. Treatment of fibromyalgia syndrome. Rheum Dis Clin North Am. 1989;15:61-71.

33. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned?. Arch Intern Med. 1999;159:777-85.

34. Crofford LJ. Pharmaceutical treatment options for fibromyalgia. Curr Rheumatol Rep. 2004;6:274-80.

35. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223-32.


Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article